Building on the success of Bellafill, its flagship regenerative biostimulatory product, Suneva Medical Inc has signed new partnership agreements with both Healeon Medical Inc and Puregraft LLC.
These two new partnerships are intended to shape the future of regenerative aesthetics, according to the company in a media release.
“The combination of our world class commercial organization and these unique and innovative aesthetic products strategically positions us for long-term growth as a leader in the regenerative aesthetic market,” says Preston Romm, CEO, Suneva Medical, in the release. “These new products will add significant breadth to Suneva’s product portfolio.”
Suneva’s partnership agreement with Healeon Medical, based in Newbury Park, Calif, is for certain markets on Healeon’s proprietary, cutting-edge PRP technology, featuring an innovative high platelet capture design, as well as for a long-term exclusive relationship on Healeon’s next generation technologies arriving to the aesthetics market mid-2019.
“Healeon Medical has a concentration on the growth of regenerative medicine, making Suneva Medical a great partner as it continues to lead this promising area of aesthetics,” states Jeff Greiner, CEO of Healeon Medical.
Suneva’s second partnership is with Solana Beach, Calif-based Puregraft LLC, which develops products that provide surgeons with purified fat for reinjection. As part of the agreement, Suneva Medical has a distribution partnership with Bimini for certain markets on their proprietary Puregraft fat grafting system for use within the regenerative skin and body care industry and an exclusive relationship on their next generation technology scheduled to launch in early to mid-year 2019, the release continues.
“Suneva Medical is a seamless connection for our Puregraft products and its next-generation technology. We look forward to growing the relationship and working together to shape the global aesthetics market,” comments Brad Conlan, CEO of Puregraft, in the release.
[Source(s): Suneva Medical Inc, PR Newswire]